Basilea Pharmaceutica, Prokaryotics Partner to Develop Anti-infective Drugs

MT Newswires · 4d ago
01:50 AM EST, 01/07/2026 (MT Newswires) -- Swiss biopharmaceutical company Basilea Pharmaceutica (BSLN.SW) partnered with US-based Prokaryotics for anti-infective drugs discovery and development. Under the deal, the partners will identify a clinical candidate, which will be developed by Basilea, according to a Wednesday release. Basilea would also be responsible for the global commercialization of the drug under an exclusive global license. Prokaryotics will receive an undisclosed upfront payment from Basilea. Further, Prokaryotics would be eligible to receive up to $48.5 million in development, regulatory, and commercial milestone payments, as well as tiered low single-digit royalties on global net sales.